The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Long-Term Treatment with Recombinant Insulin-Like Growth Factor (IGF)-I in Children with Severe IGF-I Deficiency due to Growth Hormone Insensitivity
Abstract
CONTEXT: Children with severe IGF-I deficiency due to congenital or acquired defects in GH action have short stature that cannot be remedied by GH treatment. OBJECTIVES: The objective of the study was to examine the long-term efficacy and safety of recombinant human IGF-I (rhIGF-I) therapy for short children with severe IGF-I deficiency. DESIGN: Seventy-six children with IGF-I deficiency due to GH insensitivity were treated with rhIGF-I for up to 12 yr under a predominantly open-label design. SETTING: The study was conducted at general clinical research centers and with collaborating endocrinologists. SUBJECTS: Entry criteria included: age older than 2 yr, sd scores for height and circulating IGF-I concentration less than -2 for age and sex, and evidence of resistance to GH. INTERVENTION: rhIGF-I was administered sc in doses between 60 and 120 microg/kg twice daily. MAIN OUTCOME MEASURES: Height velocity, skeletal maturation, and adverse events were measured. RESULTS: Height velocity increased from 2.8 cm/yr on average at baseline to 8.0 cm/yr during the first year of treatment (P < 0.0001) and was dependent on the dose administered. Height velocities were lower during subsequent years but remained above baseline for up to 8 yr. The most common adverse event was hypoglycemia, which was observed both before and during therapy. It was reported by 49% of treated subjects. The next most common adverse events were injection site lipohypertrophy (32%) and tonsillar/adenoidal hypertrophy (22%). CONCLUSIONS: Treatment with rhIGF-I stimulates linear growth in children with severe IGF-I deficiency due to GH insensitivity. Adverse events are common but are rarely of sufficient severity to interrupt or modify treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Laron, Z., Avitzur, Y., & Klinger, B. (1995) · Metabolism · doi:10.1016/0026-0495(95)90231-7 · Cited by 76
Cited by
Cohen, P., Rogol, A. D., Deal, C. L., Saenger, P., Reiter, E. O., Ross, J. L., Chernausek, S. D., Savage, M. O., Wit, J. M., & participants, O. B. O. T. 2. I. C. W. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0509 · Cited by 737
Self-citationThe Role of Liver-Derived Insulin-Like Growth Factor-I
Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, A., Isgaard, J., Isaksson, O., Jansson, J.-O., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 453
Deal, C. L., Tony, M., Höybye, C., Allen, D. B., Tauber, M., Christiansen, J. S., & Participants, T. 2. G. H. I. P.-W. S. C. C. G. W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3888 · Cited by 379
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P. E., Banerjee, I., Murray, P. G., & Renehan, A. G. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 364
The growth hormone receptor: mechanism of activation and clinical implications
Brooks, A. J., & Waters, M. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.123 · Cited by 357
Metadata
- Authors
- Chernausek, S. D., Backeljauw, P. F., Frane, J., Kuntze, J., Underwood, L. E., & for the GH Insensitivity Syndrome Collaborative Group
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-03-01
- Volume
- 92
- Issue
- 3
- Pages
- 902-910
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2132555220
- Cited by
- 243
- References
- 2
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Treatment with Recombinant Insulin-Like Growth Factor (IGF)-I in Children with Severe IGF-I Deficiency due to Growth Hormone Insensitivity. https://app.cochat.ai/papers/10.1210/jc.2006-1610
- The paper
- Chernausek, S. D., Backeljauw, P. F., Frane, J., Kuntze, J., Underwood, L. E., & for the GH Insensitivity Syndrome Collaborative Group. (2007). Long-Term Treatment with Recombinant Insulin-Like Growth Factor (IGF)-I in Children with Severe IGF-I Deficiency due to Growth Hormone Insensitivity. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2006-1610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.